Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.

SZSE:301096 Stock Report

Market Cap: CN¥3.9b

Hangzhou Bio-Sincerity Pharma-TechLtd Future Growth

Future criteria checks 5/6

Hangzhou Bio-Sincerity Pharma-TechLtd is forecast to grow earnings and revenue by 30.6% and 22.8% per annum respectively. EPS is expected to grow by 28.7% per annum. Return on equity is forecast to be 12.1% in 3 years.

Key information

30.6%

Earnings growth rate

28.7%

EPS growth rate

Life Sciences earnings growth30.4%
Revenue growth rate22.8%
Future return on equity12.1%
Analyst coverage

Low

Last updated09 Nov 2024

Recent future growth updates

No updates

Recent updates

We Believe That Hangzhou Bio-Sincerity Pharma-TechLtd's (SZSE:301096) Weak Earnings Are A Good Indicator Of Underlying Profitability

Nov 04
We Believe That Hangzhou Bio-Sincerity Pharma-TechLtd's (SZSE:301096) Weak Earnings Are A Good Indicator Of Underlying Profitability

Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (SZSE:301096) Soars 30% But It's A Story Of Risk Vs Reward

Sep 30
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (SZSE:301096) Soars 30% But It's A Story Of Risk Vs Reward

Market Cool On Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.'s (SZSE:301096) Earnings Pushing Shares 27% Lower

Jul 24
Market Cool On Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.'s (SZSE:301096) Earnings Pushing Shares 27% Lower

Solid Earnings May Not Tell The Whole Story For Hangzhou Bio-Sincerity Pharma-TechLtd (SZSE:301096)

Apr 29
Solid Earnings May Not Tell The Whole Story For Hangzhou Bio-Sincerity Pharma-TechLtd (SZSE:301096)

Should You Be Adding Hangzhou Bio-Sincerity Pharma-TechLtd (SZSE:301096) To Your Watchlist Today?

Mar 14
Should You Be Adding Hangzhou Bio-Sincerity Pharma-TechLtd (SZSE:301096) To Your Watchlist Today?

Earnings and Revenue Growth Forecasts

SZSE:301096 - Analysts future estimates and past financials data (CNY Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,724459-4296003
12/31/20251,406363-4774733
12/31/20241,141286-2984963
9/30/20241,025212-693-126N/A
6/30/20241,119287-647-5N/A
3/31/20241,072287-751-28N/A
12/31/20231,017272-59890N/A
9/30/2023900250-520135N/A
6/30/2023786229-531154N/A
3/31/2023673210-388289N/A
1/1/2023607194-332259N/A
9/30/2022573192-319241N/A
6/30/2022479155-194224N/A
3/31/2022425126-178117N/A
12/31/2021374111-103145N/A
9/30/2021304101-167100N/A
6/30/202126785-20480N/A
3/31/202121155-22949N/A
12/31/202020757-20154N/A
12/31/201915644-3571N/A
12/31/201882112645N/A
12/31/201726-7N/A11N/A
6/30/2017308N/A11N/A
3/31/2017275N/A6N/A
12/31/2016243N/A2N/A
9/30/2016211N/A1N/A
6/30/201616-1N/A5N/A
3/31/2016162N/A4N/A
1/1/2016165N/A3N/A
12/31/20146-2N/A1N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 301096's forecast earnings growth (30.6% per year) is above the savings rate (2.8%).

Earnings vs Market: 301096's earnings (30.6% per year) are forecast to grow faster than the CN market (25% per year).

High Growth Earnings: 301096's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 301096's revenue (22.8% per year) is forecast to grow faster than the CN market (13.5% per year).

High Growth Revenue: 301096's revenue (22.8% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 301096's Return on Equity is forecast to be low in 3 years time (12.1%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/07 00:42
End of Day Share Price 2025/01/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jiabo ZhangGuosen Securities Co., Ltd.
Yuan Yuan SunIndustrial Securities Co. Ltd.
Chaoze ZhouMinsheng Securities Co.